Is Becton, Dickinson & Co. overvalued or undervalued?

As of 17 October 2025, Becton, Dickinson & Co. has moved from an attractive to an expensive valuation grade. The company is currently overvalued, as indicated by its P/E ratio of 33, which is significantly higher than the industry average, and a PEG ratio of 2.36, suggesting that growth expectations are not being met by current earnings. Additionally, the EV to EBITDA ratio stands at 16.57, further reinforcing the perception of overvaluation.
In comparison to its peers, Becton, Dickinson & Co. has a higher P/E ratio than Abbott Laboratories at 18.36 and Thermo Fisher Scientific at 30.06, both of which are considered fairly valued. The company's recent performance has been lackluster, with a year-to-date return of -16.65%, compared to a positive return of 13.30% for the S&P 500, highlighting the disconnect between its valuation and market performance.